Biotech Growth Trust plc (The) (BIOG) Ordinary 25p
- Add to watchlist
- Create an alert
- This stock can be held in a
903.00p
912.00p
1,068.00p
967.12
903.00p
900.00p
738.00p
-7.35%
7.00p (0.78%) Previous:
7.00p
81,049
n/a
GBX
Price
-
Net Asset Value (NAV)
Performance
1 week 1W | 9.34% | 1 year 1Y | 18.82% |
---|---|---|---|
1 month 1M | 14.33% | 2 years 2Y | 5.84% |
3 months 3M | 9.7% | 3 years 3Y | 24.88% |
6 months 6M | 7.38% | 5 years 5Y | 14.59% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
Benchmark: | NASDAQ Biotechnology TR GBP |
---|---|
Annual management charge: | n/a |
Performance fee: | Yes |
Ongoing charge: | 1.20% |
Dividend yield: | n/a |
Dividend frequency: | None |
Total assets: | £332m |
Gross gearing: | 8% |
Market capitalisation:Market cap.: | £282m |
Shares in issue: | 31.52 million |
Legal structure | Closed Ended Investment Company |
Domicile: | United Kingdom |
ISIN | GB0000385517 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
NET ASSET VALUE (NAV)
Estimated NAV: | 967.12p |
---|---|
Latest actual NAV: | 969.00p |
Latest actual NAV date: | 19 November 2024 |
Premium/Discount: | -7.35% |
12m average Premium/Discount: | -7.52% |
NAV frequency: | Daily |
Security | Weight |
---|---|
Amgen Inc | 9.11% |
Biogen Inc | 4.73% |
Sarepta Therapeutics Inc | 4.59% |
QuantumPharm Inc | 3.43% |
argenx SE ADR | 3.37% |
Regeneron Pharmaceuticals Inc | 3.28% |
ACADIA Pharmaceuticals Inc | 3.12% |
Syndax Pharmaceuticals Inc | 3.10% |
Alnylam Pharmaceuticals Inc | 2.94% |
Vir Biotechnology Inc | 2.74% |
Sector | Weight |
---|---|
Healthcare | 91.71% |
Country | Weight |
---|---|
United States | 82.58% |
China | 5.05% |
Canada | 2.97% |
Switzerland | 1.11% |
Key Dates
Launch date: | 23 June 1997 |
---|---|
Financial year end: | March |
Next AGM: | July 2025 |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.